Integrated BioPharma Q2 rev $12.6M (+9.6% YoY); net income $0.1M vs loss

INTEGRATED BIOPHARMA INC

2025-Q2 EPS reported $0.01 revenue$26,231,000

Revenue $12.6M for Q2 ended Dec 31, 2024, up from $11.5M a year ago; six-month rev $26.2M (+7.4%).
Operating income $0.2M vs operating loss $0.5M in prior year quarter; six-month op income $0.7M.
Net income $0.1M ($0.00 EPS) vs net loss $0.4M ($(0.01) EPS) in prior year quarter.
Two largest contract manufacturing customers represented ~82% of total revenue in the six-month period.
Co-CEOs cite customer base expansion and core business focus as drivers of revenue growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.